This research group aims to uncover the mechanisms and molecular pathways driving cancer cell programs and progression using cutting-edge genomic technologies and with a primary focus on colorectal cancer. Its research also extends to other cancer types and genetic diseases.

The team’s current interests lie in the development of technical and bioinformatic tools that facilitate the processing and interpretation of genomic and epigenomic data, bridging the gap between next-generation technologies and clinical applications. To this end, they have created web applications and tools that make it easier to manage and access genomic data. For the study of colorectal tumorigenesis and cell differentiation processes they use human samples and in vitro models to create reference frameworks and working models for understanding the mechanisms behind malignant transformation.

The research group has also developed novel methods to interrogate genetic and epigenetic information, and established a spin-off company to translate these advances in genomic and epigenomic technologies into clinical practice. Finally, the group has developed a technique to pinpoint the epigenetic state of the "dark genome" with the aim of understanding the functional properties of specific repeat elements and how they contribute to genome regulation colon cancer cells.

Keywords: Colorectal cancer, epigenetics, biomarker, integrative molecular profiling, tumour progression.

Group leader

  • Miguel Ángel Peinado

    Miguel Ángel Peinado

    Miguel A. Peinado has a degree in Biology (Univiversity of Barcelona) and a long track of research at Hospital Clínic (Master’s thesis, 1985-1986), Hospital de Sant Pau (PhD, 1986-1989), California Inst. Biol. Res (postdoc, 1990), IRO (reincorporation contract, 1992) and as a principal investigator at IRO (1992-2005), IDIBELL (2005-2007), IMPPC (2007-2015) and IGTP (2016-). He has also had management responsibilities as Department director at IRO, Scientific coordinator at IMPPC and Deputy Director at IGTP. Currently, Peinado is codirector of the Cancer Research Translational Program (CARE) of IGTP.

    MA Peinado has participated in more than 25 research projects and has published >140 research articles, including leading multidisciplinary journals such as Nature, Science, NEJM and PNAS, and specialised journals in the fields of Genetics (Nat Genet, Nucl Acids Res, Genome Res, etc) and Cancer (JNCI, Cancer Res, J Clin Oncol, Cancer Cell, etc.). MA Peinado has also led research contracts with industry and is coinventor of five patents. Since 2015, he is CSO of Aniling, a start-up company dedicated to accelerating the transfer of Epigenetics advances to Medicine through the development of NGS technologies.

    Contact: mpeinado(ELIMINAR)
    ORCID: 0000-0002-4090-793X

Research lines

The main focus of this research group is the characterisation of the molecular mechanisms underlying cell programs and the identification of molecular markers with clinical application. The specific topics currently being developed in the lab include:

  • Chromatin architecture in cell differentiation and cancer
  • The role of repeat elements in genome structure and function
  • Clinically oriented research on the epigenetic changes involved in human cancer

Active projects

Enabling personalized colorectal cancer management by coupling unified genetic and epigenetic testing to organoid-based treatment screening (Spot & Hit)

PI: L. Coll
Funding agency: Ministerio de Ciencia e Innovación (MCINN)
Agency code: CPP2021-008602
Duration: 2022 - 2025

Proyecto CPP2021-008602 financiado por:

Proyecto CPP2021-008602 financiado por MCIN/AEI/10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR

Integration of specific and interspersed genetic and epigenetic signals as a multi-tool to type colorectal cancer (GEALUS)

PI: MA Peinado
Funding agency: Ministerio de Ciencia e Innovación (MCINN)
Agency code: PID2021-124315OB-I00
Duration: 2022 - 2025

Past projects

DEEP-GEUS: a new Artificial Intelligence assisted integrative genomic diagnostics system of Chronic Lymphocytic Leukemia

Funding agency: Centro para el Desarrollo Tecnológico Industrial (CDTI)
Agency code: IDI-20191104
Duration: 2019 - 2023

Germline predisposition to serrated polyposis syndrome: functional charaterization of candidate genes by CRISPR-CAS and organoid modeling

PI: S. Castellví
Funding agency: Fundació Marató de TV3
Agency code: 2019 2020008
Duration: 2021 - 2023

Use of artificial intelligence and systems biology for diagnosis and personalized risk assessment for inherited kidney diseases, focusing on Alport Syndrome

PIs: R Torra, MA Peinado, A Ortiz, M Vallverdú
Funding agency: Fundació Marató de TV3
Agency code: 22/C/2020
Duration: 2021 - 2023

Scientific publications

Highlighted publication

Mallona I, Díez-Villanueva A, Martín B, Peinado MA. Chainy: an universal tool for standardized relative quantification in real-time PCR. Bioinformatics. 2017 May 1;33(9):1411-1413. DOI: 10.1093/bioinformatics/btw839.

Jordà M, Díez-Villanueva A, Mallona I, Martín B, Lois S, Barrera V, Esteller M, Vavouri T, Peinado MA. The epigenetic landscape of Alu repeats delineates the structural and functional genomic architecture of colon cancer cells. Genome Res. 2017 Jan;27(1):118-132. DOI: 10.1101/gr.207522.116.

Barrera V, Peinado MA. Evaluation of single CpG sites as proxies of CpG island methylation states at the genome scale. Nucleic Acids Res. 2012 Dec;40(22):11490-8. DOI: 10.1093/nar/gks928.

Rodriguez J, Muñoz M, Vives L, Frangou CG, Groudine M, Peinado MA. Bivalent domains enforce transcriptional memory of DNA methylated genes in cancer cells. Proc Natl Acad Sci USA. 2008 Dec 16;105(50):19809-14. DOI: 10.1073/pnas.0810133105.

Wang Y, Jorda M, Jones PL, Maleszka R, Ling X, Robertson HM, Mizzen CA, Peinado MA, Robinson GE. Functional CpG methylation system in a social insect. Science. 2006 Oct 27;314(5799):645-7. DOI: 10.1126/science.1135213.

Rodriguez J, Frigola J, Vendrell E, Risques RA, Fraga MF, Morales C, Moreno V, Esteller M, Capellà G, Ribas M, Peinado MA. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res. 2006 Sep 1;66(17):8462-9468. DOI: 10.1158/0008-5472.CAN-06-0293.

Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet. 2006 May;38(5):540-9. DOI: 10.1038/ng1781.

Risques RA, Moreno V, Ribas M, Marcuello E, Capellà G, Peinado MA. Genetic pathways and genome-wide determinants of clinical outcome in colorectal cancer. Cancer Res. 2003 Nov 1;63(21):7206-14. PMID: 14612515.

González-García I, Moreno V, Navarro M, Martí-Ragué J, Marcuello E, Benasco C, Campos O, Capellà G, Peinado MA. Standardized approach for microsatellite instability detection in colorectal carcinomas. J Natl Cancer Inst. 2000 Apr 5;92(7):544-9. DOI: 10.1093/jnci/92.7.544.

Arribas R, Capellà G, Tórtola S, Masramon L, Grizzle WE, Perucho M, Peinado MA. Assessment of genomic damage in colorectal cancer by DNA fingerprinting: prognostic applications. J Clin Oncol. 1997 Oct;15(10):3230-40. DOI: 10.1200/JCO.1997.15.10.3230.



- Recerca, Projectes

La investigadora Sofía España rep una ajuda de 140.000€ de la Asociación Española Contra el Cáncer

La Dra. Sofía España, investigadora del grup de recerca Mecanismes i Vies del Càncer de l'IGTP i del Grup de Recerca Aplicada en Oncologia de Badalona (B·ARGO) IGTP-Institut Català d'Oncologia (ICO) ha estat una de les beneficiàries de les prestigioses Ayudas Clínico Junior atorgades per la Asociación Española Contra el Cáncer. Aquesta ajuda li permetrà compaginar la seva tasca assistencial amb la recerca, centrant-se en el desenvolupament d'una eina de diagnòstic poc invasiva que permeti classificar els diferents tipus de càncer colorectal, avançant cap a una medicina de precisió.

- Campus Can Ruti

Es presenta CARE el Programa Translacional de Recerca en Càncer de l’IGTP

CARE, el Programa Translacional de Recerca en Càncer (Translational Program in Cancer Research), és el primer programa transversal promogut per l'Institut de Recerca Germans Trias i Pujol (IGTP), que vol ser nexe d'investigadors del càncer interessats a establir ponts entre la recerca bàsica i la clínica, amb una clara vocació per traslladar al pacient el coneixement i les eines que es generen al laboratori.

+ Notícies